Eledon Pharmaceuticals (ELDN)

• Market cap: $113M
• 1 day: -11.27%
• 5 days: -53.79%
• 1 month: -30.51%
• 3 months: -28.95%
• 6 months: -34.15%
• Year to date: -55.94%
• 1 year: -60.79%
• 5 years: -90.54%
• 10 years: -99.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Employees: 31